Clinical Trials in the Netherlands / NCT07501780
Starting soon Observational

Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice

NCT07501780 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2026-03-15
Last updated
2026-03-30

Condition(s) studied

Basal Cell Carcinoma of SkinOptical Coherence Tomography (OCT)NeoplasmsNeoplasms, Basal CellCarcinoma, Basal Cell (BCC)Real-world StudyImplementation

Study summary

Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions.

This retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged ≥18 years * LC-OCT performed as part of diagnostic evaluation between January 2025 and June 2025 at Mohs clinics in the Netherlands * Histopathological results (biopsy or excision) and/or 6-12 month clinical follow-up data available Exclusion Criteria: * Patients \<18 years of age * Cases without histopathological confirmation or available follow-up data

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maastricht University Medical Center + Maastricht Limburg

More Maastricht University Medical Center trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07501780 on ClinicalTrials.gov ↗ ← All trials in the Netherlands